Germ cell tumor of the testis (GCT) is a curable cancer even when it is widely metastatic; however, outcomes can differ based on tumor histology. Chemo-resistance in certain phenotypes, such as teratoma and yolk sac tumor, contributes to poor clinical outcomes in some patients with GCT. Despite this resistance to S-YSTemic therapy, many of these tumor subtypes remain amenable to surgical resection and possible cure. In this study, we report on a series of seven patients highlighting two chemo-resistant subtypes of nonseminomatous germ cell tumor (NSGCT), sarcomatoid yolk sac tumor (S-YST), and epithelioid trophoblastic tumor (ETT) for which early resection rather than additional salvage chemotherapy or high-dose intense chemotherapy might provide a superior clinical outcome and enhance cure rate.
Journal of clinical medicine. 2024 Jun 12*** epublish ***
Jamaal C Jackson, Darren Sanchez, Andrew C Johns, Matthew T Campbell, Ahmet M Aydin, Neriman Gokden, Sanjay Maraboyina, Jason L Muesse, John F Ward, Louis L Pisters, Niki M Zacharias, Charles C Guo, Shi-Ming Tu
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Division of Urology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Division of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Division of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.